Selenium nanoparticles selectively target KRAS G13D mutation

◇ RESEARCH

Researchers developed selenium nanoparticles that specifically inhibit tumors driven by the KRAS G13D mutation—a variant that currently has no approved targeted therapies—by upregulating the tumor suppressor GPX2 and blocking metastasis pathways. (Advanced Science)